SCHEMBL1382397

SCHEMBL1382397

CCOC(=O)c1sc2ccccc2c1OCc1cccc(C#N)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
ALDH1A1 P00352 2/20 0.53
KMT2A Q03164 2/20 0.53
MAPT P10636 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
NOD2 Q9HC29 1/20 0.51
GAA P10253 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NMT1 P30419 2/20 0.48
SENP5 Q96HI0 10/20 0.47
SENP2 Q9HC62 10/20 0.47
SENP1 Q9P0U3 10/20 0.47
USP2 O75604 1/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
SETD7 Q8WTS6 1/20 0.44
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4632917 0.89 KMT2A (0.56) LMNAALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL4633884 0.86 SENP2 (0.51) ALDH1A1SENP5SENP2SENP1USP2
SCHEMBL4632951 0.86 FFAR1 (0.45) LMNAALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL4633875 0.85 ALDH1A1 (0.67) LMNAALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL4633538 0.84 NMT1 (0.62) LMNAALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL4604237 0.82 SENP2 (0.48) SENP5SENP2SENP1USP2FFAR1
SCHEMBL4632990 0.81 ALDH1A1 (0.57) LMNAALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL4632949 0.80 KMT2A (0.69) LMNAALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL4633874 0.80 ALDH1A1 (0.56) LMNAALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL4632942 0.80 ALDH1A1 (0.56) LMNAALDH1A1KMT2AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4786545-B2 2011-10-05 JP claimed
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP claimed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US claimed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US claimed
EP-1685121-A1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES MERCK PATENT GmbH (DE) 2006-08-02 EP claimed
WO-2005054225-A1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2005-06-16 WO claimed
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives GPR119, INSR, GLP1R LMNA 3220/4885ALDH1A1 668/4885KMT2A 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.